Physician profile
Nasrin Arbabi
NPI 1881655462
$11,798.49
in general payments reported to CMS, 2019-2025
35 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,911 · 2020: $862 · 2021: $2,126 · 2022: $2,997 · 2023: $1,052 · 2024: $1,451 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,901.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,381.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,120.24 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $1,698.74 | 2022 | |
| Lilly USA, LLC | $779.63 | 2019-2025 | Zepbound, Mounjaro, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $660.58 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $638.81 | 2021 | |
| Amgen INC. | $535.23 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $329.65 | 2021-2025 | Vraylar |
| Eisai INC. | $253.28 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $226.99 | 2021-2024 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $178.26 | 2019-2020 | |
| Allergan, INC. | $160.07 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $154.73 | 2019-2021 | |
| Astellas Pharma US INC | $148.40 | 2019-2024 | Veozah |
| Si-Bone, INC. | $146.95 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $146.37 | 2019 | |
| Axsome Therapeutics, INC. | $126.33 | 2023-2024 | Auvelity, Sunosi |
| Aimmune Therapeutics, INC. | $124.56 | 2025 | Zenpep |
| Heartflow, INC. | $121.76 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $114.46 | 2023-2025 | |
| Intuitive Surgical, INC. | $107.63 | 2024 | |
| Merck Sharp & Dohme LLC | $100.28 | 2019 | |
| Glaxosmithkline, LLC. | $79.72 | 2019-2025 | Shingrix, Arexvy |
| Pfizer INC. | $69.12 | 2023-2025 | |
| Inspire Medical Systems, INC. | $54.60 | 2024 | Inspire |
| Jazz Pharmaceuticals INC. | $39.70 | 2021-2022 | |
| Therapeuticsmd, INC. | $33.10 | 2019-2022 | |
| Ibsa Pharma INC. | $30.82 | 2025 | Licart, Flector, Tirosint |
| Mayne Pharma Commercial LLC | $24.66 | 2023 | |
| Phadia US INC. | $19.74 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.57 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.60 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.22 | 2025 | |
| Exact Sciences Corporation | $17.10 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasrin Arbabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.